The Recombinant Human TNFRSF12A/TWEAKR/CD266 Protein is a biologically active recombinant protein that plays a significant role in various cellular processes and signaling pathways in human biology. This protein is widely employed in immunological research, cell biology studies, protein-protein interaction analyses, and therapeutic development, providing researchers with a reliable tool for investigating TNFRSF12A/TWEAKR/CD266 function and its implications in health and disease.
This product (SKU: RPCB0263) is produced using HEK293 cells and features a C-hFc&His tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 32.30 kDa with an observed molecular weight of 35-40 kDa under denaturing conditions, achieving ≥ 90 % as determined by SDS-PAGE;≥ 90 % as determined by HPLC.. Functional bioactivity has been validated through rigorous quality control assays, confirming its suitability for demanding research applications.
High quality, high purity and low endotoxin recombinant Recombinant Human TNFRSF12A/TWEAKR/CD266 Protein (RPCB0263), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 0.1 EU/μg of the protein by LAL method.
Purity:
≥ 90 % as determined by SDS-PAGE;≥ 90 % as determined by HPLC.
Formulation:
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation.
Bio-Activity:
Measured by its ability to inhibit TWEAK-induced apoptosis in HT-29 human colon adenocarcinoma cells. The ED 50 for this effect is 2-12 μg/mL in the presence of 1 μg/mL recombinant human TWEAK.
Measured by its binding ability in a functional ELISA. Immobilized Human TNFSF12 at 2 μg/mL (100 μL/well) can bind Human TNFRSF12A with a linear range of 0.1-2.3 ng/mL.
Measured by its ability to inhibit the TWEAK-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED 50 for this effect is 20-80 ng/mL in the presence of 15 ng/mL recombinant human TWEAK.
Reconstitution:
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
Fn14 (tumor necrosis factor receptor superfamily, member 12A), also known as TNFRSF12A, is the receptor for TNFSF12/TWEAK. Human and mouse TNFRSF12A share 82% aa sequence identity. TNFRSF12A transcript was expressed at high levels in heart, placenta, and kidney, at intermediate levels in lung, skeletal muscle, and pancreas, and at low levels in brain and liver. In addition, elevated TNFRSF12A expression was found in human liver cancer cell lines and hepatocellular carcinoma specimens. TNFRSF12A is the weak inducer of apoptosis in some cell types. It promotes angiogenesis and the proliferation of endothelial cells. TNFRSF12A may modulate cellular adhesion to matrix proteins.
Recombinant Human TNFRSF12A/TWEAKR/CD266 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.
The purity of Human TNFRSF12A/FN14/TWEAKR Protein (RPCB0263) was greater than 90% as determined by SEC-HPLC.
Recombinant Human TNFRSF12A inhibits the TWEAK-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 20-80 ng/mL in the presence of 15 ng/mL recombinant human TWEAK.
